Care ownership
is why the CMA measures share of beds in a small catchment. The difficulty is that a landlord’s brand is invisible to families. Two homes can trade under different names and share an owner. I expect more pressure for transparency about who ultimately owns and controls a home.
TCHE: What lessons should the sector draw from the Welltower/CMA process? MM: There are four lessons from my perspective. One: the test is local, so a nationally modest deal can still fail in one town. Two: property deals are caught, because acquiring the real estate with influence over the operator counts. Three: completing first and asking later is expensive, because the CMA can freeze integration. Four: the outcome was workable. A 649-home deal survived with ten homes sold and four more given a new operator, about 2 per cent of the portfolio. So, this is a cost of doing business to plan for, not a barrier. Practical steps I now advise: map local
bed shares at heads of terms, decide whether to brief the CMA, allocate the risk in the contract (conditions, long-stop dates, who bears a forced disposal) and model the remedies case for funders.
The undertakings show what a remedy
costs: buyers signed up before acceptance, three months to complete, a trustee sale at no minimum price if that fails, and a 10-year bar on buying the homes back.
TCHE: Should quality of care play a bigger role in debates about ownership and consolidation? MM: I think it should, but it helps to be clear about who does what. The CMA ‘s job is competition, and it treats quality as something rivalry protects: if a home has no local rival, the pressure to keep standards up weakens. The CQC ‘s job is quality, but it looks at each home and each provider, and has limited sight of the ownership chain above. The gap between those two is where the debate sits. Quality did get into the Welltower remedy by the back door: every buyer had to warrant it could ensure ‘safe, high-quality regulated care’, and no sale could complete before the CQC approved the buyer. CQC Market Oversight under the Care
Act 2014 covers financial sustainability of the largest providers, not quality or ownership suitability. A share sale does not require a new CQC registration, so the regulator may only be notified, not asked. The Casey
Commission is the obvious route for change. A quality test on ownership has risks. It could slow rescue deals for failing homes, where speed protects residents. It could deter the long-term capital the sector needs to replace old stock. Any new test needs a clear timetable and clear criteria. Uncertainty is priced by investors and lenders.
TCHE: Will we see further consolidation? MM: Yes, but in a different pattern. I expect fewer very large portfolio deals and more regional build-ups, because the local share test bites hardest on buyers who are already everywhere. Expect some reshuffling too: portfolio owners trading homes with each other to stay under local thresholds. Local bed-share mapping becomes a
standard diligence workstream alongside commercial, CQC and property.
TCHE: Will we see more international capital? MM: Yes. North American REITs and European investors remain interested, and Welltower shows a very large deal can be cleared with remedies. The CareTrust £1.1bn LNT deal followed within a
ONE TRUSTED PARTNER.
Forbes Professional Forbes Professional 0345 070 2335 |
info@forbes-professional.co.uk |
www.forbes-professional.co.uk | since 1926 0345 070 2335 |
info@forbes-professional.co.uk |
www.forbespro.co.uk | since 1926 November 2026
www.thecarehomeenvironment.com 17
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
